Last updated on December 2018

Patients with metastatic prostate cancer will receive either talazoparib or placebo in combination with enzalutamide to determine if the addition of talazoparib to enzalutamide will provide additional benefit when compared to enzalutamide alone.


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Urologic Cancer | Cancer/Tumors | Prostate Cancer | Cancer Treatment
  • Age: Between 18 - 100 Years
  • Gender: Male

  • Patient must have metastatic prostate cancer currently on androgen deprivation therapy, castrate with testosterone of < 50 ng/dL.
  • Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan and has progression of disease defined by psa progression, soft tissue disease, or bone disease. 
  • Exclusion is progression of metastatic disease CRPC during taxane chemotherapy, or novel therapy after onset of CRPC, history of another malignancy within 3 years.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.